{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T18:29:38Z","timestamp":1771957778298,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.ygyno.2010.01.048","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T05:13:38Z","timestamp":1268802818000},"page":"429-439","source":"Crossref","is-referenced-by-count":31,"title":["Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapies"],"prefix":"10.1016","volume":"117","author":[{"given":"Kathleen M.","family":"Darcy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2010.01.048_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV epithelial ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2010.01.048_bib2","first-page":"1235","article-title":"Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study","volume":"63","author":"Farley","year":"2003","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2008.08.020","article-title":"Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage and suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study","volume":"111","author":"Darcy","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2009.02.009","article-title":"Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group study","volume":"113","author":"Farley","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib5","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ygyno.2009.05.012","article-title":"Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study","volume":"114","author":"Darcy","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2010.01.048_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2010.01.048_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ygyno.2010.01.048_bib8","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1200\/JCO.2003.11.052","article-title":"Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Havrilesky","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ygyno.2006.02.014","article-title":"Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study","volume":"101","author":"Secord","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.01.048_bib10","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ygyno.2006.02.014","article-title":"The role of methylation in the regulation of angiogenic inhibitors in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"101","author":"Secord","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2010.01.048_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2007.03.021","article-title":"Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"106","author":"Secord","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2008.11.030","article-title":"Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status and angiogenic marker expression: a Gynecologic Oncology Group study","volume":"112","author":"Rubatt","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2010.01.048_bib13","first-page":"283","article-title":"Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations: a Gynecologic Oncology Group study","volume":"80","author":"Havrilesky","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2010.01.048_bib14","first-page":"S54","article-title":"Correlations between cell cycle regulatory genes and relationship to ovarian cancer prognosis: a Gynecologic Oncology Group study","volume":"104","author":"Havrilesky","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ygyno.2009.07.035","article-title":"Association between the N-terminally truncated (\u0394N) p63\u03b1 (\u0394Np63\u03b1) isoform and debulking status, VEGF expression and progression-free survival in previously-untreated, advanced stage epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"115","author":"Jewell","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2010.01.048_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.20314","article-title":"Association between serum levels of soluble tumor necrosis factor receptors\/CA 125 and disease progression in patients with epithelial ovarian malignancy: a Gynecologic Oncology Group study","volume":"101","author":"Burger","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage ovarian carcinoma: a Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib18","first-page":"499","article-title":"Alterations in cyclin E and p27 in early epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"84","author":"Farley","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib19","first-page":"S43","article-title":"Angiogenic marker alteration in high-risk stage I or II epithelial ovarian cancer","volume":"104","author":"Garg","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.ygyno.2010.01.048_bib20","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozol","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ygyno.2010.01.048_bib21","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/0008-5472.CAN-06-4076","article-title":"A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy","volume":"67","author":"Darcy","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2010.01.048_bib22","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e16504","article-title":"A Gynecologic Oncology Group study of frequent copy number aberrations in DNA repair genes and other genomic regions in stage I serous ovarian cancers","volume":"27","author":"Pejovic","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2010.01.048_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e16544","article-title":"iGenomic Viewer, a Gynecologic Oncology Group software library for the creation of highly customizable, portable, interactive, and linked visualizations of high throughput genomic data","volume":"27","author":"Gaile","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2010.01.048_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ygyno.2010.01.048_bib25","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2010.01.048_bib26","first-page":"157","article-title":"The prognostic significance of germline BRCA1 mutations in epithelial ovarian cancer: a Gynecologic Oncology Group Study","volume":"88","author":"Gallion","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2010.01.048_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cancergencyto.2004.12.017","article-title":"High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors","volume":"159","author":"Wilcox","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2010.01.048_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1525-1438.2006.00504.x","article-title":"BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study","volume":"16","author":"Thrall","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2010.01.048_bib29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ygyno.2004.07.015","article-title":"Analysis of CHEK2 gene for ovarian cancer susceptibility","volume":"95","author":"Baysal","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"21","key":"10.1016\/j.ygyno.2010.01.048_bib30","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1200\/JCO.2008.16.1323","article-title":"Relationship between ERCC1 polymorphisms and disease progression and survival in the Gynecologic Oncology Group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer","volume":"26","author":"Krivak","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15s","key":"10.1016\/j.ygyno.2010.01.048_bib31","first-page":"302s","article-title":"Relationship between ERCC1 polymorphism, disease progression and survival in GOG0182: a Gynecologic Oncology Group phase III trial of platinum-based chemotherapy in women with advanced stage epithelial ovarian or primary peritoneal cancer","volume":"26","author":"Krivak","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2010.01.048_bib32","first-page":"S9","article-title":"BRCA1\/BRCA2 polymorphisms and prognosis in women with optimally-resected stage III epithelial ovarian cancer treated on GOG Protocol 172: a Gynecologic Oncology Group study","volume":"112","author":"Krivak","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"15S","key":"10.1016\/j.ygyno.2010.01.048_bib33","first-page":"s293","article-title":"A Gynecologic Oncology Group study of associations between polymorphisms in ABC transporter genes (ABCB1, ABCC2 and ABCG2) and outcome in advanced stage epithelial ovarian cancer treated with platinum and taxane chemotherapy","volume":"27","author":"Darcy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ygyno.2004.11.037","article-title":"Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6\u201312months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study","volume":"96","author":"Garcia","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2010.01.048_bib35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.07.023","article-title":"A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"115","author":"Aghajanian","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2007.11.029","article-title":"Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian or cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study","volume":"108","author":"Secord","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2010.01.048_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody (Trastuzumab) in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J. Clin. Oncol"},{"issue":"15","key":"10.1016\/j.ygyno.2010.01.048_bib38","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"33","key":"10.1016\/j.ygyno.2010.01.048_bib39","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15S","key":"10.1016\/j.ygyno.2010.01.048_bib40","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545375","article-title":"Relationship between angiogenic markers and clinicopathologic factors\/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC)","volume":"26","author":"Han","year":"2008","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ygyno.2010.01.048_bib41","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.2007.14.3420","article-title":"Phase II evaluation of imatinib methylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"26","author":"Schilder","year":"2008","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ygyno.2010.01.048_bib42","first-page":"4811","article-title":"Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies","volume":"9","author":"Zorn","year":"2003","journal-title":"Clin Cancer Res."},{"issue":"18","key":"10.1016\/j.ygyno.2010.01.048_bib43","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","article-title":"Gene expression of serous, endometrioid, and clear cell types of ovarian and endometrial cancer","volume":"11","author":"Zorn","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.ygyno.2010.01.048_bib44","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1038\/sj.onc.1208210","article-title":"A role for Ubc9 in tumorigenesis","volume":"24","author":"Mo","year":"2007","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ygyno.2010.01.048_bib45","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/1078-0432.CCR-03-0439","article-title":"Alternative splicing of the multidrug resistance protein 1\/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20","volume":"10","author":"He","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"34","key":"10.1016\/j.ygyno.2010.01.048_bib46","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1038\/sj.onc.1210307","article-title":"Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro","volume":"26","author":"He","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib47","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1006\/gyno.2001.6430","article-title":"BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study","volume":"83","author":"Smith","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2010.01.048_bib48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/gyno.2002.6615","article-title":"Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a Gynecologic Oncology Group study","volume":"85","author":"Reedy","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2010.01.048_bib49","doi-asserted-by":"crossref","first-page":"594.604","DOI":"10.1158\/1055-9965.EPI-07-2703","article-title":"A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study","volume":"17","author":"Greene","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"22","key":"10.1016\/j.ygyno.2010.01.048_bib50","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1093\/hmg\/ddp372","article-title":"Common variants in 8q24, LSP1 and 2q35 and breast cancer risk for BRCA1 and BRCA2 mutation carriers","volume":"18","author":"Antoniou","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ygyno.2010.01.048_bib51","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0171-9335(99)80077-6","article-title":"Selective changes in EGF receptor expression and function during the proliferation, functional differentiation and apoptosis of mammary epithelial cells","volume":"78","author":"Darcy","year":"1999","journal-title":"Euro J Cell Biol"},{"issue":"1","key":"10.1016\/j.ygyno.2010.01.048_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/002215540004800107","article-title":"Changes in ErbB2 (HER-2\/neu), ErbB3 and ErbB4 during the growth, differentiation and apoptosis of normal rat mammary epithelial cells","volume":"48","author":"Darcy","year":"2000","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.ygyno.2010.01.048_bib53","unstructured":"http:\/\/www.sigmaaldrich.com\/life-science\/cell-biology\/learning-center\/pathway-slides-and\/signaling-pathways.html."},{"key":"10.1016\/j.ygyno.2010.01.048_bib54","unstructured":"http:\/\/www.sigmaaldrich.com\/life-science\/cell-biology\/learning-center\/pathway-slides-and\/regulatory-cascade-of-cyclin-gene-expression.html."},{"key":"10.1016\/j.ygyno.2010.01.048_bib55","unstructured":"http:\/\/www.sigmaaldrich.com\/life-science\/cell-biology\/learning-center\/pathway-slides-and\/g1-and-s-phases-of-the-cell-cycle.html."},{"issue":"2","key":"10.1016\/j.ygyno.2010.01.048_bib56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2008.08.006","article-title":"Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature","volume":"64","author":"Vilmar","year":"2009","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2010.01.048_bib57","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.4161\/cc.4.9.2027","article-title":"Good timing in the cell cycle for precise DNA repair by BRCA1","volume":"4","author":"Durant","year":"2005","journal-title":"Cell Cycle"},{"issue":"19","key":"10.1016\/j.ygyno.2010.01.048_bib58","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2007.11.3902","article-title":"Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway","volume":"26","author":"Weberpals","year":"2008","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ygyno.2010.01.048_bib59","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-09-0096","article-title":"Recent advances in cancer therapy targeting proteins involved in DNA double-strand repair","volume":"15","author":"Bolderson","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810001289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825810001289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T18:28:23Z","timestamp":1635100103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825810001289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0090825810001289"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2010.01.048","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}